A Medical Update: HER2-Positive Breast Cancer
In HER2-positive disease, the breast cancer tests positive for a protein called human epidermal growth factor receptor 2, or HER2. Though about 20 percent of breast cancers are HER2-positive, it’s possible you never heard of it before you were diagnosed.
Knowing what is unique about HER2-positive disease can help you talk with healthcare providers and loved ones to make the best treatment decisions.
During our free August webinar with Chau T. Dang, MD, you will learn about
- HER2-positive breast cancer and what tests will tell you the cancer’s HER2 status
- today’s available treatment options and new treatments under study, whether you have early-stage or metastatic HER2-positive disease
- barriers to getting targeted medicine, as well as ways to overcome these barriers
About Our Speaker
Her research focuses on developing more effective and less toxic treatments for women affected by breast cancer. Dr. Dang’s particular interest is combination therapies that include treatment with chemotherapy for people diagnosed with early-stage or metastatic HER2-positive breast cancer. Dr. Dang and her colleagues are working to develop markers or predictors that identify which people may be at risk for developing early, and possibly late, targeted treatment-related side effects such as heart damage, so that they can design early methods to prevent or minimize these side effects.